Top 5 Movers and Shakers Leading Today Market Buzz

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  13 Nov 2025
 

•   BRAG  
   
  +1.67%
•   BWEN  
   
  +2.36%
•   CLBT  
   
  -0.10%
•   CURI  
   
  -0.85%
•   IPWR  
   
  -12.09%

$CURI surged as traders reacted to a double dose of catalysts: a fresh 0.08 dividend declaration and growing optimism around CuriosityStream positioning in the emerging AI video training data licensing market. With volume exploding to nearly ten times its average, the sharp upside seems driven by income oriented investors and speculative momentum tied to AI related themes. When a micro cap name sees this type of volume and narrative push, it often reflects fast crowding rather than long term conviction, but today CURI clearly led the buzz.

$CLBT extended its rally with a strong fifth consecutive green session, gaining more than 20% on heavy volume. The sustained move suggests more than random rotation as traders appear to be betting on continued execution in Cellebrite digital intelligence segment while law enforcement tech spending remains resilient. There was no specific fresh headline today, but persistent accumulation hints at institutional interest while trending sentiment adds fuel.

$BWEN jumped after Broadwind reported strong third quarter results, beating on revenue and earnings while raising confidence in its FY25 outlook. The nearly 19% surge came with volume more than seven times average, showing that the market took the print seriously. Improving demand visibility across energy and industrial fabrication lifted expectations and turned BWEN into one of today stronger fundamental based movers.

$BRAG climbed nearly 18% as Bragg Gaming reaffirmed its full year outlook despite posting a GAAP EPS loss of 0.09 euro. Revenue of 26.8 million euro met expectations and management commentary in the earnings call pointed toward continued progress in scaling its content distribution presence. For a small cap gaming technology company, reaffirmed guidance in an uncertain environment can act as a powerful catalyst and today volume spike confirmed renewed interest.

$SEE added more than 16% after analyst chatter suggested Sealed Air may be worth somewhere in the mid 40s per share in a potential takeover scenario. With volume jumping to almost eight times normal and RSI entering overbought territory, the move looks like a combination of buyout speculation and momentum chasing. Even so, traders favor packaging companies when real M and A talk surfaces and SEE reflected that enthusiasm.

$IPWR fell nearly 27% after Ideal Power missed earnings expectations with a GAAP EPS of minus 0.32. Although revenue is less important for a company still early in commercialization, the miss increased concerns about cash burn and development timelines for its B TRAN technology. Limited liquidity amplified the drop as sellers outnumbered bids throughout the session.

$PSFE posted one of the sharpest declines of the day, dropping almost 28% after a disappointing third quarter report that missed both revenue and earnings guidance while management cut its full year outlook. With shares already falling for six sessions in a row, sentiment was fragile and traders reacted with near capitulation selling. Volume soared to almost ten times average, confirming broad frustration with the outlook.

$MGRX collapsed more than 32% despite headlines highlighting a partnership with major drug makers to distribute weight loss medications directly. The reaction suggests traders doubted the economics or scale of the arrangement and saw it as more promotional than material. Enormous volume revealed widespread skepticism as the market repriced the risk around the company business model.

$KXIN continued a severe slump with a 62% drop after five consecutive red sessions. With no meaningful catalyst, the selloff appears tied to liquidity stress, dilution fears or structural challenges affecting the company capital position. When a low priced stock accelerates downward at this pace it often signals forced selling and collapsing confidence.

$KRRO suffered the harshest decline, plunging 79% after Korro Bio reported disappointing early stage trial results for its RNA editing therapy KRRO 110. Alongside a heavy loss of 1.92 per share on minimal revenue the company also announced a 34% workforce reduction which highlighted the severity of its pipeline setback. Multiple negative updates hitting at once led to a near total repricing of future expectations.

View All Headlines